LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Seliciclib | 10.0 | uM | LJP5 | 3 | J01 | 72 | hr | 1401 | 2624 | 4223 | 0.6214 | 0.4333 |
| SK-BR-3 | Ruxolitinib | 10.0 | uM | LJP5 | 1 | O13 | 72 | hr | 1401 | 3782 | 4223 | 0.8956 | 0.8437 |
| SK-BR-3 | Ruxolitinib | 10.0 | uM | LJP5 | 2 | O13 | 72 | hr | 1401 | 4130 | 4223 | 0.9780 | 0.9670 |
| SK-BR-3 | Ruxolitinib | 10.0 | uM | LJP5 | 3 | O13 | 72 | hr | 1401 | 3813 | 4223 | 0.9029 | 0.8547 |
| SK-BR-3 | XL147 | 10.0 | uM | LJP5 | 1 | G07 | 72 | hr | 1401 | 3633 | 4223 | 0.8603 | 0.7909 |
| SK-BR-3 | XL147 | 10.0 | uM | LJP5 | 2 | G07 | 72 | hr | 1401 | 3837 | 4223 | 0.9086 | 0.8632 |
| SK-BR-3 | XL147 | 10.0 | uM | LJP5 | 3 | G07 | 72 | hr | 1401 | 3641 | 4223 | 0.8622 | 0.7937 |
| SK-BR-3 | Saracatinib | 10.0 | uM | LJP6 | 1 | D07 | 72 | hr | 1401 | 2276 | 4223 | 0.5389 | 0.3099 |
| SK-BR-3 | Saracatinib | 10.0 | uM | LJP6 | 2 | D07 | 72 | hr | 1401 | 2088 | 4223 | 0.4944 | 0.2433 |
| SK-BR-3 | Saracatinib | 10.0 | uM | LJP6 | 3 | D07 | 72 | hr | 1401 | 1938 | 4223 | 0.4589 | 0.1901 |
| SK-BR-3 | Selumetinib | 10.0 | uM | LJP6 | 1 | M07 | 72 | hr | 1401 | 4528 | 4223 | 1.0722 | 1.1081 |
| SK-BR-3 | Selumetinib | 10.0 | uM | LJP6 | 2 | M07 | 72 | hr | 1401 | 4105 | 4223 | 0.9720 | 0.9582 |
| SK-BR-3 | Selumetinib | 10.0 | uM | LJP6 | 3 | M07 | 72 | hr | 1401 | 3944 | 4223 | 0.9339 | 0.9011 |
| SK-BR-3 | Sirolimus | 10.0 | uM | LJP6 | 1 | L13 | 72 | hr | 1401 | 2352 | 4223 | 0.5569 | 0.3369 |
| SK-BR-3 | Sirolimus | 10.0 | uM | LJP6 | 2 | L13 | 72 | hr | 1401 | 2509 | 4223 | 0.5941 | 0.3925 |
| SK-BR-3 | Sirolimus | 10.0 | uM | LJP6 | 3 | L13 | 72 | hr | 1401 | 2737 | 4223 | 0.6481 | 0.4733 |
| SK-BR-3 | Sorafenib | 10.0 | uM | LJP6 | 1 | B07 | 72 | hr | 1401 | 2631 | 4223 | 0.6230 | 0.4357 |
| SK-BR-3 | Sorafenib | 10.0 | uM | LJP6 | 2 | B07 | 72 | hr | 1401 | 2913 | 4223 | 0.6898 | 0.5357 |
| SK-BR-3 | Sorafenib | 10.0 | uM | LJP6 | 3 | B07 | 72 | hr | 1401 | 2536 | 4223 | 0.6005 | 0.4021 |
| SK-BR-3 | SU11274 | 10.0 | uM | LJP5 | 1 | J07 | 72 | hr | 1401 | 1379 | 4223 | 0.3265 | -0.0080 |
| SK-BR-3 | SU11274 | 10.0 | uM | LJP5 | 2 | J07 | 72 | hr | 1401 | 1573 | 4223 | 0.3725 | 0.0608 |
| SK-BR-3 | SU11274 | 10.0 | uM | LJP5 | 3 | J07 | 72 | hr | 1401 | 1488 | 4223 | 0.3524 | 0.0306 |
| SK-BR-3 | Fedratinib | 10.0 | uM | LJP5 | 1 | L01 | 72 | hr | 1401 | 1043 | 4223 | 0.2470 | -0.1271 |
| SK-BR-3 | Fedratinib | 10.0 | uM | LJP5 | 2 | L01 | 72 | hr | 1401 | 987 | 4223 | 0.2337 | -0.1469 |
| SK-BR-3 | Fedratinib | 10.0 | uM | LJP5 | 3 | L01 | 72 | hr | 1401 | 1319 | 4223 | 0.3123 | -0.0292 |